OECDReference EN/AU/PS1088626
Tenofovir Disoproxil Emtricitabine Mylan 300/200 Tablets
Official information organised for easier consultation. The source publication remains authoritative.
Identification
Product identification
- Product
- Tenofovir Disoproxil Emtricitabine Mylan 300/200 Tablets
Official information
Risk and measures
- Risk or hazard
- Potential for broken and/or split tablets. In the event a broken/split tablet is consumed, this may result in an ineffective dose if the tablet is not taken in its entirety. A broken or split tablet may lead to ineffective dosing, which may increase the risk of adverse health effects.
- Recommendations
- Consumers that have been prescribed Tenofovir Disoproxil Emtricitabine Mylan 300/200 should consult their treating physician for advice. Consumers that have any unexpired product should return the product to their pharmacist for a refund. A TGA web statement can be found at https://www.tga.gov.au/alert/tenofovir-disoproxil-emtricitabine-mylan-300200 For further information, please contact Alphapharm on 1800 274 276.
Official information
Economic operators
- Manufacturer
- Alphapharm Pty Ltd
Territory
Geography
- Distribution
- Retirada en Australia
- Country of recall
- Australia
Provenance and context
NagameAlert distinguishes content published by the source from its organisation and normalisation. Values marked “NagameAlert” belong to that processing layer. Always check measures, scope and updates in the official publication.